Search This Blog

Wednesday, April 16, 2025

Arkansas, Indiana push to ban candy, soda from SNAP program

 Republican governors in Arkansas and Indiana are asking the federal government for permission to ban soda and candy purchases with food stamps.

Arkansas Gov. Sarah Huckabee Sanders said her goal is to improve the health of the nearly 350,000 people in her state who use the Supplemental Nutrition Assistance Program (SNAP), the Associated Press reported.

"Taxpayers are subsidizing poor health," Sanders said Tuesday during a news conference with U.S. Agriculture Secretary Brooke Rollins. "We're paying for it on the front end and the back end."

In Indiana, Gov. Mike Braun made a similar announcement alongside U.S. Health Secretary Robert F. Kennedy Jr. and Dr. Mehmet Oz, who now heads the Centers for Medicare and Medicaid Services. Braun said the state's changes would focus on putting "the focus back on nutrition—not candy and ."

If approved, Arkansas' plan would take effect in July 2026. It would ban the use of SNAP to buy:

  • Regular, low- and no-calorie sodas
  • Fruit and vegetable drinks with less than 50% juice
  • Artificially sweetened candy
  • Candy made with flour, such as Kit Kat bars

However, the plan would allow people to use SNAP for hot rotisserie chicken, which is not allowed now.

Indiana's plan also targets candy and soda. Braun added new work rules for SNAP users, brought back income verification rules and even ordered a review of possible payment mistakes in the program, The Associated Press said.

SNAP, which helped nearly 42 million Americans in 2024 and cost about $100 billion, is overseen by the U.S. Department of Agriculture but run by individual states.

Benefits can be used to buy almost any food item but not alcohol, tobacco and hot meals.

Since 2004, six other states have tried to get federal waivers to restrict certain food purchases through SNAP. None were approved.

Congress would likely need to change law to allow these restrictions, experts say.

"They changed our food system in this country so that it is poison to us," Kennedy said. "We can't be a strong nation if we are not a strong people."

Critics and anti-hunger groups say the changes unfairly target low-income families.

"They just seem to be targeting a specific population without having data that says that they are the issue or that this is going to improve," said Gina Plata-Nino, a deputy director at the Food Research and Action Center, a nonprofit advocacy group.

The American Beverage Association and the National Confectioners Association also criticized the plans.

"SNAP participants and non-SNAP participants alike understand that chocolate and candy are treats—not meal replacements," National Confectioners Association spokesman Chris Gindlesperger said.

https://medicalxpress.com/news/2025-04-arkansas-indiana-candy-soda-snap.html

Repetitive transcranial magnetic stimulation shows promise in Alzheimer's treatment

 Santa Lucia Foundation IRCCS-led research is reporting that repetitive transcranial magnetic stimulation (rTMS) targeting the precuneus may slow the progression of cognitive decline, impairments in daily functioning, and behavioral symptoms in patients with Alzheimer's disease. Patients who received 52 weeks of rTMS showed slower deterioration across clinical outcomes compared to those who received sham stimulation.

rTMS delivers magnetic pulses to targeted brain areas and is considered a non-invasive brain stimulation technique. It is used to treat conditions like depression and  by inducing small electrical currents in brain cells to modify  and help reduce symptoms.

The precuneus brain region has been identified as a promising site for stimulation due to its early involvement in Alzheimer's pathology, including amyloid deposition, gray matter loss, and disrupted connectivity within brain networks.

In animal models, rTMS has been shown to reduce beta-amyloid and phosphorylated tau, increase neurogenic proteins such as brain-derived neurotrophic factor, and decrease pro-inflammatory cytokines including IL-6 and TNF-α.

A previous Phase II trial found that 24 weeks of precuneus-targeted rTMS slowed cognitive decline and reduced loss of daily functional abilities in patients with mild-to-moderate Alzheimer's disease. Next, researchers wanted to see if extending rTMS treatment to 52 weeks could continue to preserve cognition and function over the longer time frame.

In the study, "Effects of 52 weeks of precuneus rTMS in Alzheimer's disease patients: a randomized trial," published in Alzheimer's Research & Therapy, researchers conducted a sham-controlled, randomized, and double-blind pilot trial.

The cohort included 48 patients diagnosed with mild-to-moderate Alzheimer's disease. A total of 27 patients were assigned to receive rTMS, and 21 were assigned to a sham stimulation group. Among them, 31 were continuing from a previous 24-week trial that used the same experimental design, and 17 were newly enrolled and randomized.

Continuing participants remained in their original treatment group and extended their participation by an additional 28 weeks, bringing their total duration of rTMS or sham exposure to 52 weeks. Newly enrolled participants began treatment at the start of the trial and completed a full 52-week course, which included a two-week intensive phase followed by weekly maintenance sessions.

Stimulation was delivered using neuronavigated transcranial magnetic stimulation paired with electroencephalography (TMS-EEG) to personalize the location and intensity for each participant. Each session involved 40 two-second trains at 20 Hz spaced over 20 minutes, totaling 96,000 pulses per patient across the trial.

Patients who received  experienced a slower rate of cognitive and functional decline compared to those in the sham group. The primary outcome, measured by change in Clinical Dementia Rating Scale–Sum of Boxes, showed an estimated mean change of 1.36 points in the stimulation group compared to 2.45 points in the sham group after 52 weeks.

Functional ability, assessed using the Alzheimer's Disease Cooperative Study scale for activities of daily living, declined by an estimated 1.5 points in the rTMS group and 11.6 points in the sham group.

Cognitive performance, as measured by the Alzheimer's Disease Assessment Scale cognitive subscale, showed a mean increase of 5.9 points in the rTMS group versus 10.4 points in the sham group. In this context, higher scores reflect greater impairment.

Scores on the Mini Mental State Examination declined by 1.1 points in the rTMS group and 3.9 points in the sham group. Behavioral symptoms, measured with the Neuropsychiatric Inventory, also favored the rTMS group, with an estimated change of 3.28 points versus 6.91 points in the sham condition. Subscales showed measurable improvements in apathy, euphoria, and appetite-related disturbances.

Completion rate across both groups was 68%. Most participant withdrawals were linked to disruptions caused by the COVID-19 pandemic. Mild adverse effects such as headache or scalp discomfort were reported in both groups and resolved without medical intervention.

Stronger baseline connectivity within the brain's default mode network was associated with a more favorable clinical response in the rTMS group, suggesting that brain activity profiling could help identify patients most likely to benefit from this treatment.

Researchers concluded that rTMS targeting the precuneus may reduce the progression of  in patients with mild-to-moderate Alzheimer's disease. The treatment also appeared to delay deterioration in daily functioning and reduce behavioral disturbances. Patients receiving rTMS did not show significant loss of autonomy over the one-year period, as measured by standardized assessments.

Some behavioral symptoms, including apathy, euphoria, and appetite-related changes, also improved in patients receiving rTMS. Fewer declines in activities of daily living may translate into lower caregiver burden and greater patient independence during early disease stages.

Larger studies across multiple sites are needed to confirm these findings and could also explore how rTMS could be used in combination with drug therapies that target amyloid, tau, or neuroinflammation.

More information: Giacomo Koch et al, Effects of 52 weeks of precuneus rTMS in Alzheimer's disease patients: a randomized trial, Alzheimer's Research & Therapy (2025). DOI: 10.1186/s13195-025-01709-7


https://medicalxpress.com/news/2025-04-repetitive-transcranial-magnetic-alzheimer-treatment.html

Made In China Vs Made In America

 While China’s status as the world’s largest manufacturing hub seems to be a law of nature these days - one only challenged by President Trump - that hasn’t always been the case. 

In fact, as Statista's Felix Richter shows in the chart below, as recently as 2009, the U.S. trumped China in manufacturing output as measured by total value added in the sector.

Infographic: China's Rise to Manufacturing Dominance | Statista 


China’s manufacturing output climbed from roughly $134 billion in 1980 to roughly $4.8 trillion in 2023. 

During that time, China’s share of global manufacturing output climbed from 5 percent to around 30 percent, while former manufacturing leader the United States saw its share drop from 21 to 17 percent. 

In 2001, the U.S. share of global manufacturing peaked at 28 percent, but China’s accession to the WTO in 2001, which opened the country up to the world economy, quickly changed the balance of power.

https://www.zerohedge.com/economics/made-china-vs-made-america

Computer-Aided Colonoscopy Not Ready for Prime Time

 An American Gastroenterological Association (AGA) multidisciplinary panel has reached the conclusion that no recommendation can be made for or against the use of computer-aided detection (CADe)–assisted colonoscopy for colorectal cancer (CRC), the third most common cause of cancer mortality in the United States.

The systematic data review is a collaboration between the AGA and The BMJ’s MAGIC Rapid RecommendationsThe BMJ issued a separate recommendation against CADe shortly after the AGA guideline was published. 

Led by Shahnaz S. Sultan, MD, MHSc, of the Division of Gastroenterology, Hepatology, and Nutrition at University of Minnesota, Minneapolis, and recently published in Gastroenterology, found only very low certainty of GRADE-based evidence for several critical long-term outcomes, both desirable and undesirable. These included the following: 11 fewer CRCs per 10,000 individuals and two fewer CRC deaths per 10,000 individuals, an increased burden of more intensive surveillance colonoscopies (635 more per 10,000 individuals), and cost and resource implications.

This technology did, however, yield an 8% (95% CI, 6-10) absolute increase in the adenoma detection rate (ADR) and a 2% (95% CI, 0-4) increase in the detection rate of advanced adenomas and/or sessile serrated lesions. “How this translates into a reduction in CRC incidence or death is where we were uncertain,” Sultan said. “Our best effort at trying to translate the ADR and other endoscopy outcomes to CRC incidence and CRC death relied on the modeling study, which included a lot of assumptions, which also contributed to our overall lower certainty.”

The systematic and meta-analysis included 41 randomized controlled trials with more than 32,108 participants who underwent CADe-assisted colonoscopy. This technology was associated with a higher polyp detection rate than standard colonoscopy: 56.1% vs 47.9% (relative risk [RR], 1.22, 95% CI, 1.15-1.28). It also had a higher ADR: 44.8% vs 37.4% (RR, 1.22; 95% CI, 1.16-1.29).

But although CADe-assisted colonoscopy may increase ADR, it carries a risk for overdiagnosis, as most polyps detected during colonoscopy are diminutive (< 5 mm) and of low malignant potential, the panel noted. Approximately 25% of lesions are missed at colonoscopy. More than 15 million colonoscopies are performed annually in the United States, but studies have demonstrated variable quality of colonoscopies across key quality indicators.

“Artificial intelligence [AI] is revolutionizing medicine and healthcare in the field of GI [gastroenterology], and CADe in colonoscopy has been brought to commercialization,” Sultan told Medscape Medical News. “Unlike many areas of endoscopic research where we often have a finite number of clinical trial data, CADe-assisted colonoscopy intervention has been studied in over 44 randomized controlled trials and numerous nonrandomized, real-world studies. The question of whether or not to adopt this intervention at a health system or practice level is an important question that was prioritized to be addressed as guidance was needed.”

Commenting on the guideline but not involved in its formulation, Larry S. Kim, MD, MBA, a gastroenterologist in Denver, said his practice group has used the GI Genius AI system in its affiliated hospitals but has so far chosen not to implement the technology at its endoscopy centers. “At the hospital, our physicians have the ability to utilize the system for select patients or not at all,” he told Medscape Medical News.

The fact that The BMJ reached a different conclusion based on the same data, evidence-grading system, and microsimulation, Kim added, “highlights the point that when evidence for benefit is uncertain, underlying values are critical.” In declining to make a recommendation, the AGA panel balanced the benefit of improved detection of potentially precancerous adenomas vs increased resource utilization in the face of unclear benefit. “With different priorities, other bodies could reasonably decide to recommend either for or against CADe.”

The Future

According to Sultan, gastroenterologists need a better understanding of patient values and preferences and the value placed on increased adenoma detection, which may also lead to more lifetime colonoscopies without reducing the risk for CRC. “We need better intermediate- and long-term data on the impact of adenoma detection on interval cancers and CRC incidence,” she said. “We need data on detection of polyps that are more clinically significant such as those 6-10 mm in size, as well as serrated sessile lesions. We also need to understand at the population or health system level what the impact is on resources, cost, and access.”

Ultimately, the living guideline underscores the trade-off between desirable and undesirable effects and the limitations of current evidence to support a recommendation, but CADe has to improve as an iterative AI application with further validation and better training.

With the anticipated improvement in software accuracy as AI machine learning reads increasing numbers of images, Sultan added, “the next version of the software may perform better, especially for polyps that are more clinically significant or for flat sessile serrated polyps, which are harder to detect. We plan to revisit the question in the next year or two and potentially revise the guideline.”

These guidelines were fully funded by the AGA Institute with no funding from any outside agency or industry.

Sultan is supported by the US Food and Drug Administration. Co-authors Shazia Mehmood Siddique, Dennis L. Shung, and Benjamin Lebwohl are supported by grants from the National Institute of Diabetes and Digestive and Kidney Diseases. Theodore R. Levin is supported by the Permanente Medical Group Delivery Science and Applied Research Program. Cesare Hassan is a consultant for Fujifilm and Olympus. Peter S. Liang reported doing research work for Freenome and advisory board work for Guardant Health and Natera.

Kim is president-elect of the AGA. He disclosed no competing interests relevant to his comments.

https://www.medscape.com/viewarticle/computer-aided-colonoscopy-not-ready-prime-time-aga-clinical-2025a1000929

Will AI Be the End of the Prior Auth Paper Chase or Cause More Chaos?

 In 2025 alone, doctors and legislators across the country have already introduced more than 100 pieces of legislation meant to reform prior authorization. The cumbersome approval process is a leading cause of burnout among doctors, and changing it is a top priority of the American Medical Association (AMA). According to a 2024 survey, 93% of physicians say that prior authorization has led to patient harm.

Leaders in the health-tech arena believe prior authorization is ripe for an artificial intelligence (AI)-driven transformation. The problem is that most doctors aren’t on board. 

In February, the AMA reported that 61% of physicians believe that using AI in prior authorization will increase denial rates and delay patient care. Moreover, medical associations in at least five states have introduced legislation meant to limit AI’s use in patient decisions. 

Though innovators promise speed and better access, doctors say that insurers could easily use the technology to make approvals and appeals even more taxing. Medscape Medical News spoke to prior authorization experts, including doctors on the front lines, and they all agree that AI has the potential to change the game — but only if prior auth gets a makeover. If the process isn’t reformed to be more transparent and patient-centric, AI will simply make a flawed system work faster.

Could AI Fix the System?

“The danger of layering AI on top of a broken system is that, while it offers a lot in terms of efficiency, if you introduce more efficiency and speed into that system, you just speed up the rate at which you do bad things,” said Amy Killelea, JD, assistant research professor at Georgetown University’s Center on Health Insurance Reforms, Washington, DC. 

It’s unclear how widely AI is already used in prior authorization. A new survey of 93 health insurers released at the National Association of Insurance Commissioners (NAIC) conference in March 2025 reported that 92% use, plan to use, or are exploring AI and machine learning. The preliminary results were not explicit about how health insurers are employing AI. 

If they’re using the algorithm to collect relevant data from the medical record more quickly, that’s a use case no one would have a problem with, Killelea said. But algorithms making decisions about claims and denying care is a problem. Cigna and UnitedHealth already face class action lawsuits after investigations showed they used AI to deny claims without doctor oversight. 

According to Leslie Lenert, MD, a primary care physician who researches computing at the Medical University of South Carolina in Charleston, companies used rule-based AI to compare claims to insurer criteria. These kinds of if/then algorithms are too fragile for the complex reasoning it takes to evaluate claims, Lenert said. The result was thousands of claims denied at a time without a meaningful doctor review. 

The Myth of Anti-Tech Doctors

Doctors are rallying to slow the use of AI in prior authorization — but contrary to popular belief and some headlines, it’s not because they’re anti-technology. 

Most doctors are pro-AI. “AI is probably a great way to save time and control cost. We have no problem with AI being involved in the first look” at a claim, said Sarah Lee-Davisson, MD, a general surgeon and an advocate for an Arizona bill regulating AI in prior authorization. She said that the apprehension has more to do with the nebulous prior authorization process. 

Even without AI, prior authorization is already a black box. Physicians often get little or no feedback on why a claim is denied and the approval metrics are constantly changing. KFF analysis of ACA Marketplace plans in 2023 found that the most common reason listed for denial, at 34%, was “other reason not listed.” 

Brian Callaghan, MD, a neurologist at the University of Michigan in Ann Arbor, Michigan, recently spent months working to get one of his patients rituximab. The claim was initially denied without a clear reason or a clear option to appeal. By contrast, he never has problems getting the drug for his patients at Veterans Affairs, where there’s only one payer. 

“With private insurance, you feel like they are trying to deny as many things as possible,” said Callaghan, who is also lead author on a 2024 paper on using AI to refine prior authorization. Some form of cost containment is essential, but it needs to be easy, he said. He said that having a complex process means fewer things are approved — not because of science or clinical appropriateness, but because the process is challenging. 

While payers are heavily regulated in other areas, there are few to no guardrails in place to make sure that prior authorization is based on clinical data and in the patient’s best interest. And payers have a clear conflict of interest, said Lenert. 

It's not technology that makes physicians nervous; it’s an imbalance of power, Lenert added. “Insurance companies have unlimited access to resources to deny claims and plenty of incentive to do so,” he said. “And providers often don’t have access to any additional resources [to push back].” 

Callaghan agrees. Doctors already put in long hours and have designated staff members handling prior authorization. While he’s a firm believer that AI could help solve some of these problems if prior authorization continues as it is — complicated, ever-changing, and hard to speak to a peer physician — then AI may very well make the process even harder, he said. 

Holding Out Hope

Still, doctors hope that if prior authorization is made more transparent, AI could relieve a huge burden. The technology could minimize time spent on paperwork for both sides. And if the first look at a claim is automated, approvals could happen faster. 

Start-ups in the space are already building AI-based tools to consolidate disjointed insurance portals, speed up pre-visit insurance verification, determine where prior authorization is needed, and automatically submit electronic requests to appropriate payers. 

In the future, more sophisticated generative AI algorithms probably could tackle denials, Lenert said. “Even if [AI could] turn around claim denials faster and give an explicit reason why, that would be a service.” That would give doctors far more information than they have to go on today. 

But as long as payers “can say no without taking responsibility for the need to act, that isn’t fair,” Lenert said. That’s true, with or without AI. The industry needs a new standard of denials. “If it isn’t fully transparent, it’s fully wrong,” he added.

A Breaking Point

At the state level, more legislation on prior authorization continues to be introduced, the NAIC reported. “It’s reached a breaking point,” Killelea said. Prior authorization has transitioned from a healthcare industry debate to a public concern. “We are already seeing states jump into the fray.”

The aim is not to eliminate prior authorization but to set up some guardrails so the system can’t be used to delay or deny clinically appropriate care. There’s plenty of AI-specific legislation too. California and Colorado have already passed legislation limiting automated decision-making systems in prior authorization. Texas, Arizona, Connecticut, and Indiana have similar bills in the works. 

“We have no problem with AI being involved in the first look [at a claim],” said Lee-Davisson in Arizona, “but if there’s going to be a denial of a test or medicine or surgery, we certainly think it warrants a doctor looking at it.” 

Zeke Silva, MD, a private practice interventional radiologist in Houston, is backing a similar bill in Texas. “We accept that prior authorization has some role. We accept that algorithms have some role in patient care,” he said. “But if you’re denying care, it should be by someone trained to practice medicine.” 

https://www.medscape.com/viewarticle/will-ai-be-end-prior-auth-paper-chase-or-cause-more-chaos-2025a100091g

Behind the Cortisol Trend: Misinformation Could Drive Unnecessary Testing

 Cortisol detoxing” is currently trending on social media. Influencers recommend exercises, special diets, supplements, and cortisol testing to reduce what they call the “stress hormone.”

Some primary care clinicians and other specialists say they are fielding requests from patients to order cortisol testing, probably in part because of social media misinformation. But cortisol testing can help diagnose a limited number of conditions, such as Cushing syndrome or adrenal insufficiency, both rare conditions.

Disha Narang, MD, an endocrinologist and director of Obesity Medicine at Endeavor Health in Chicago, said she often gets asked to test cortisol levels by patients who receive misinformation about the hormone on social media.

“My cortisol levels were so high, I was puffy all over my body, I couldn’t sleep at night, but I was fatigued all day long,” said one woman on TikTok promoting a supplement as a treatment for high cortisol. Meanwhile, a dietitian on TikTok explained how exhaustion after exercising could be a sign that cortisol levels are low and adrenal glands need to recover.

“There’s no science behind any of this,” Narang said.

Primary care clinicians should be aware of the sizable room for error when administering the test and analyzing test results, experts said.

“Overuse and sometimes inappropriate use of cortisol profiling by providers unaware of interpreting this data has led to patients erroneously being prescribed exogenous cortisol supplements, leading to iatrogenic/medication-induced Cushing’s and permanent adrenal insufficiency,” said Preethika S. Ekanayake, MD, an endocrinologist at UC San Diego Health.

Should You Test Cortisol Levels?

The Endocrine Society only has cortisol test guidelines for endocrine conditions, such as Cushing syndrome and adrenal insufficiency, and does not for more general symptoms, such as stress or chronic fatigue, said Maria Fleseriu, MD, the former chair of the Clinical Guidelines Committee at the organization.

And testing cortisol levels in patients who do not have symptoms of either hormonal disorder is not recommended, Fleseriu, director of the Pituitary Center at Oregon Health & Science University in Portland, Oregon, said.

Cushing syndrome, or pathologically elevated cortisol, is considered rare, affecting up to 70 out of 1 million people per year. The Endocrine Society does not recommend any treatment to lower cortisol in the absence of this disease.

Adrenal insufficiency affects 300 per million people, and symptoms include fatigue, poor appetite, salt cravings, and vertigo.

Without clinical suspicion of these conditions, cortisol testing can lead to false-positive results, said Katie Guttenberg, MD, associate professor of medicine in the Division of Endocrinology, Diabetes and Metabolism at UTHealth Houston.

Cortisol also naturally fluctuates throughout the day, she said, making a single blood test an unreliable measure of the hormone level.

Sleep patterns, mental health conditions, and acute stress can all affect the hormone, Fleseriu said.

“A spike in cortisol levels at a given moment doesn’t necessarily indicate a larger health problem,” Fleseriu said.

False Positives

Patients with chronic stress, metabolic syndrome, uncontrolled diabetes, or eating disorders are prone to producing false-positive results for elevated cortisol, said Fleseriu.

Many common nonendocrine conditions such as depression and alcoholism can lead to physiologic hypercortisolism, known as pseudo–Cushing syndrome, Guttenberg said.

Clinicians who are unaware of the pseudocondition may mistake elevated cortisol results for signs of true Cushing syndrome and order unnecessary testing, radiographic evaluation, invasive procedures, and medication, Guttenberg said.

Physiologic hypercortisolism is “particularly common in patients presenting with major depressive disorders,” said Guttenberg. “That is why I do not generally recommend measuring cortisol in this population.”

The treatment for physiologic hypercortisolism should be focused on the underlying condition, such as treatment for depression, said Guttenberg.

People who are pregnant or people taking medications and supplements such as contraceptives, glucocorticoids, and biotin can also produce a falsely elevated cortisol level, Guttenberg said.

Narang said she has cared for patients who were referred by primary care clinicians who conducted a cortisol test in the afternoon, when levels tend to be low, triggering a false-positive result and leading to suspicion of adrenal insufficiency.

False positives for adrenal insufficiency “may lead to unnecessary follow-up testing including lab work or imaging, and increased health anxiety,” said Priya Jaisinghani, MD, a clinical assistant professor in the Department of Medicine at NYU Grossman School of Medicine, New York City.

Educating Patients 

Education of patients on the role of cortisol in the body can help alleviate patient fears, Ekanayake said.

“The adrenal glands are very smart glands,” said Ekanayake. “I often educate my patients that there does not need to be extra assistance that we as individuals need to provide for the adrenal glands to remain healthy.”

Except in the case of Cushing syndrome and adrenal insufficiency, “these glands do not have failures or underfunction with age or stress,” Ekanayake said.

“Patients are hearing about cortisol from social media,” Narang said. “Various influencers might say that you need to ask your doctor about adrenal fatigue if you’ve been feeling tired and drained. But that’s not a real diagnosis.”

Clinicians should also educate patients who are focused on their cortisol levels on their broader health behaviors, Jaisinghani said. This might include counseling on sleep habits, stress management, and diet.

“These are the foundations of overall well-being and often have a greater impact on long-term health,” Jaisinghani said.

https://www.medscape.com/viewarticle/behind-cortisol-trend-misinformation-could-drive-unnecessary-2025a100090t

5 things you should never reveal to ChatGPT if you want to protect your privacy

 People turn to ChatGPT for all kinds of things — couples therapy, help with writing a professional email, turning pictures of their dogs into humans — letting the artificial intelligence platform in on some personal information.

And apparently, there are a few specific things you should never share with the chatbot.

When you type something into a chatbot, “you lose possession of it,” Jennifer King, a fellow at the Stanford Institute for Human-Centered Artificial Intelligence, told the Wall Street Journal.

“Please don’t share any sensitive information in your conversations,” OpenAI writes on their website, while Google urges Gemini users not to “…enter confidential information or any data you wouldn’t want a reviewer to see.”

On that note, here are the five things no one should tell ChatGPT or an AI chatbot.

Identity information

Don’t reveal any identifying information to ChatGPT. Information such as your Social Security number, driver’s license and passport numbers, as well as date of birth, address and phone numbers should never be shared.

Some chatbots work to redact them, but it’s safer to avoid sharing this information at all.

“We want our AI models to learn about the world, not private individuals, and we actively minimize the collection of personal information,” an OpenAI spokeswoman told WSJ.

Medical results

While the healthcare industry values confidentiality for patients to protect their personal information as well as discrimination, AI chatbots are not typically included in this special confidentiality protection.

If you feel the need to ask ChatGPT to interpret lab work or other medical results, King suggested cropping or editing the document before uploading it, keeping it “just to the test results.”

Financial accounts

Never reveal your bank and investment account numbers. This information can be hacked and used to monitor or access funds.

Login information

It seems that there could be reasons to provide a chatbot with your account usernames and passwords due to the rise of their ability to perform useful tasks, but these AI agents aren’t vaults and don’t keep account credentials secure. It’s a better idea to put that information into a password manager.

Proprietary corporate information

If you’re using ChatGPT or other chatbots for work — such as for drafting emails or editing documents — there’s the possibility of mistakenly exposing client data or non-public trade secrets, WSJ said.

Some companies subscribe to an enterprise version of AI or have their own custom AI programs with their own protections to protect from these issues.

If you still want to get personal with the AI chatbot, there are ways to protect your privacy. According to WSJ, your account should be protected with a strong password and multi-factor authentication.

Privacy-conscious users should delete every conversation after it’s over, Jason Clinton, Anthropic’s chief information security officer, told the outlet, adding that companies typically permanently get rid of “deleted” data after 30 days.

https://nypost.com/2025/04/15/tech/five-things-you-should-never-reveal-to-chatgpt-if-you-want-to-protect-your-privacy/